Intellia Therapeutics, Inc. (NTLA)
NASDAQ: NTLA · Real-Time Price · USD
11.16
-0.95 (-7.84%)
At close: Nov 10, 2026, 4:00 PM EST
11.17
+0.01 (0.09%)
After-hours: Nov 10, 2026, 6:13 PM EST

Intellia Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
52.8967.6757.8836.2852.1233.05
Revenue Growth
-8.07%16.92%59.55%-30.40%57.69%-43.01%
Gross Profit
-218.03-256.78-349.04-398.79-367.86-196.75
Operating Income
-436.85-440.99-534.26-515.29-458.16-267.85
Net Income
-426.14-412.69-519.02-481.19-474.19-267.89
Earnings Per Share
-3.35-3.81-5.25-5.42-6.16-3.78
EPS Growth
------

Cash & Debt

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
614.81605.13861.731,0121,2621,086
Total Debt
230.1493.33210.2115.35130.774.02
Net Cash (Debt)
384.66511.81651.53896.741,1311,012
Net Cash Growth
-32.74%-21.45%-27.34%-20.73%11.78%81.34%
Net Cash Per Share
3.034.726.5910.1014.7014.28

Cash Flow & CapEx

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-355.17-394.74-348.88-394.09-333.29-225.03
Capital Expenditures
-2.9-1.13-5.78-13.99-13.56-12.76
Free Cash Flow
-358.08-395.87-354.66-408.07-346.85-237.79
Free Cash Flow Growth
------

Margins

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
------
Operating Margin
-826.00%-651.67%-923.10%-1420.51%-879.04%-810.37%
Pretax Margin
-805.75%-609.85%-896.77%-1326.51%-909.78%-810.49%
Profit Margin
-805.75%-609.85%-896.77%-1326.51%-909.78%-810.49%
FCF Margin
-677.06%-584.99%-612.78%-1124.94%-665.46%-719.41%

Valuation

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingNov '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
29.6415.3920.5275.2757.06266.22